China: Boray Data raises Series B; Tiansheng Pharma valuation rises to $986m

Chinese companies are still actively raising fund through both specialised investment firms and the capital market. Boray Data, a Big Data company, has completed a Series B round worth tens of millions of dollars from CASH Capital and other investors. Meanwhile, Tiansheng Pharmaceutical, a private equity-backed company, listed its shares on the Shenzhen Stock Exchange on May 19 and is valued at about $986 million.

Boray Data raises 8-digit Series B investment led by CASH Capital

Boray Data, a Beijing-based big data firm, has raised tens of millions of US dollars in its Series B fundraising round, led by local venture capital fund CASH Capital Investment Management, according to Chinese media.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter